Abstract:Background Paclitaxel and docetaxel are commonly used for metastatic breast cancer in the People’s Republic of China. To improve the safety and efficacy of paclitaxel, an albumin-bound formulation (nab) is now available in the People’s Republic of China (Abraxane®). To provide health economic data for the key stakeholders, a cost-utility analysis comparing nab-paclitaxel to docetaxel, both as alternatives to paclitaxel, was conducted. Methods A meta-analysis of clinical outcomes Phase III trials comparing nab-paclitaxel (260 mg/m2 every [q] 3 weeks) or branded docetaxel (100 mg/m2 q 3 weeks), to solvent-based branded paclitaxel (175 mg/m2 q 3 weeks) was undertaken to provide safety and clinical data. Resource use data for the delivery of anticancer therapy and for the treatment of grade 3/4 toxicity was collected from a time and motion study conducted in three Chinese cancer centers and from a survey of clinicians. Using the Time Trade-Off technique, health utility estimates were derived from interviewing 28 breast cancer patients from one cancer center in the People’s Republic of China. All costs were reported in 2014 US dollars. Results Nab-paclitaxel had the most favorable safety profile, characterized with the lowest incidence of grade 3/4 neutropenia, febrile neutropenia, anemia, and stomatitis. When the median number of cycles delivered from the clinical trials was applied, nab-paclitaxel had a cost per course of $19,752 compared with $8,940 and $13,741 for paclitaxel and docetaxel, respectively. As an alternative to paclitaxel, the cost per quality-adjusted life-year (QALY) gained with nab-paclitaxel suggested better value than with docetaxel ($57,900 vs $130,600). Conclusion Nab-paclitaxel appears to be a cost-effective option compared with docetaxel and paclitaxel, for metastatic breast cancer in the People’s Republic of China.

Reconciling quantum trajectories and stationary quantum distributions in single-photon polarization states

Dual-Energy Computed Tomography in Cardiothoracic Vascular Imaging

Dual-Energy CT in Cardiothoracic Imaging: Current Developments

Cardiovascular Computed Tomography in the Diagnosis of Cardiovascular Disease: Beyond Lumen Assessment

Dual energy imaging in cardiothoracic pathologies: A primer for radiologists and clinicians

Dual-Energy CT: New Horizon in Medical Imaging

Neuroradiology Applications of Dual and Multi-energy Computed Tomography

Clinical Application of PET Myocardial Perfusion Imaging

New advances in cardiac computed tomography

CT Myocardial Perfusion Imaging: A New Frontier in Cardiac Imaging

Description of a Sexually Dimorphic Oribatid Mite (Arachnida: Acari: Oribatida) from Canopy Habitats of the Ryukyu Archipelago, Southwestern Japan

Dual-Energy CT of the Thorax

Virtual non-calcium dual-energy CT: clinical applications

Applications of dual energy computed tomography in abdominal imaging

Approach to the Patient with Hypertension

Cardiovascular magnetic resonance: applications and practical considerations for the general cardiologist

Quantitative assessment of motion effects in dual-source dual energy CT and dual-source photon-counting detector CT

Cardiovascular Applications of Photon-Counting CT Technology: A Revolutionary New Diagnostic Step

Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective

Cardiac CT: why, when, and how : Update 2019

The clinical utility of new cardiac imaging modalities in Australasian clinical practice